Innovent focuses on developing high-end biopharmaceutical drugs which benefit the health of ordinary Chinese people at affordable prices.
Innovent has attracted a team of over 300 highly skilled and experienced staff with various expertise in drug discovery, cell line construction, process scale-up, commercial manufacturing and quality control etc. In addition to in-house development, Innovent also partners with world-class biopharma companies and institutes to develop advanced therapeutic molecules for unmet medical needs in China and globally.
Currently, Innovent has advanced a product portfolio consisting of 10 antibodies targeted towards over 12 indications in three major disease areas including oncology, inflammatory disease and ophthalmology. Two of the pipeline products have been granted with the national “Mega Innovative Drug Program” designation.